Literature DB >> 30771355

Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.

Nicolas M Intagliata1, Stephen H Caldwell2, Armando Tripodi3.   

Abstract

Portal vein thrombosis unrelated to solid malignancy is common in patients with cirrhosis, but less frequently observed in patients without cirrhosis. Prompt diagnosis and management of acute symptomatic portal vein thrombosis are essential. Failure to detect and treat thromboses can result in mesenteric ischemia, chronic cavernous transformation, and complications of portal hypertension. In patients with cirrhosis, development of portal vein thrombosis is often insidious and remains undetected until its incidental detection. Management of portal vein thrombosis in patients with cirrhosis is more controversial. However, there are data to support treatment of specific patients with anticoagulation agents. We review the common and distinct features of portal vein thromboses in patients without liver tumors, with and without cirrhosis.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Fibrosis; Hepatic; Therapy

Mesh:

Year:  2019        PMID: 30771355     DOI: 10.1053/j.gastro.2019.01.265

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  59 in total

1.  The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins.

Authors:  Ran Hui; Zhe Li; Zongjie Liu; Xiuping Liu; Heping Deng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 2.  Anticoagulation in patients with advanced liver disease: an open issue.

Authors:  Francesco Violi; Lorenzo Loffredo; Daniele Pastori
Journal:  Intern Emerg Med       Date:  2020-10-18       Impact factor: 3.397

3.  Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis.

Authors:  Yanyan Wu; Hongyu Li; Tiansong Zhang; Zhaohui Bai; Xiangbo Xu; Giovanni Battista Levi Sandri; Le Wang; Xingshun Qi
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

4.  The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis.

Authors:  Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Kevin Troy; Thomas Schiano; John Mascarenhas
Journal:  Blood Adv       Date:  2020-02-25

Review 5.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

Review 6.  Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis.

Authors:  Huan Chen; Jiaming Lei; Sicheng Liang; Gang Luo; Mingming Deng; Muhan Lü
Journal:  Can J Gastroenterol Hepatol       Date:  2021-04-21

7.  The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease.

Authors:  Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Steven Naymagon; John Mascarenhas; Thomas Schiano
Journal:  Inflamm Bowel Dis       Date:  2021-01-19       Impact factor: 5.325

8.  Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case-control study.

Authors:  Zhanjuan Gao; Jingrun Zhao; Xiaofeng Liu; Senlin Li; Minghui Wang; Yanjing Gao
Journal:  Hepatol Int       Date:  2021-07-22       Impact factor: 6.047

Review 9.  Acute Mesenteric Ischemia.

Authors:  Florian Kühn; Tobias S Schiergens; Ernst Klar
Journal:  Visc Med       Date:  2020-08-04

10.  Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment.

Authors:  Chenyang Zhan; Vinay Prabhu; Stella K Kang; Clayton Li; Yuli Zhu; Sooah Kim; Sonja Olsen; Ira M Jacobson; Nabil N Dagher; Brendan Carney; Ryan M Hickey; Bedros Taslakian
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.